Abstract

Breast Cancer Biomarkers From Discovery to Early Validation by Proteomics

Janne Lehtio, Associate Professor, Karolinska Institutet

Breast cancer is the most common form of cancer among females with about 1.15 million new patients annually worldwide. Endocrine treatment with tamoxifen has been the cornerstone for the treatment of breast cancer for over thirty years. However, drug resistance is a significant clinical problem in this group, and about one-third of women treated with tamoxifen for 5 years will have recurrent disease. Here we have applied quantitative proteomics for experimental systems biology analysis of cellular response to Tamoxifen treatment comparing sensitive and resistant cells. Further, we have performed clinical validation and protein interaction analysis of selected key proteins related to the drug response.